Galmed Pharmaceuticals (NASDAQ: GLMD) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Galmed Pharmaceuticals to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, valuation and dividends.
This table compares Galmed Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Galmed Pharmaceuticals Competitors||-5,310.77%||-218.27%||-39.48%|
This table compares Galmed Pharmaceuticals and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Galmed Pharmaceuticals||$470,000.00||-$16.95 million||-7.96|
|Galmed Pharmaceuticals Competitors||$284.49 million||$34.10 million||77.13|
Galmed Pharmaceuticals’ peers have higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Galmed Pharmaceuticals has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals’ peers have a beta of 6.92, indicating that their average stock price is 592% more volatile than the S&P 500.
This is a summary of recent recommendations for Galmed Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Galmed Pharmaceuticals Competitors||882||3256||11745||235||2.70|
Galmed Pharmaceuticals currently has a consensus price target of $20.75, suggesting a potential upside of 134.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.58%. Given Galmed Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Galmed Pharmaceuticals is more favorable than its peers.
Insider and Institutional Ownership
9.9% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Galmed Pharmaceuticals peers beat Galmed Pharmaceuticals on 8 of the 13 factors compared.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.